Director Geraldine Pannu buys 2,072 Processa (PCSA) shares in market

Rhea-AI Filing Summary

Processa Pharmaceuticals director Geraldine Pannu reported an open-market purchase of Common Stock. On March 31, 2026, she bought 2,072 shares at $2.535 per share, bringing her direct holdings to 2,188 shares. This was a straightforward open-market buy with no derivatives involved.

Insider Trade Summary

Net Buyer: 2,072 shares ($5,253)

Net Buy 1 txn

Insider Pannu Geraldine

Role Director

Bought 2,072 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,072	$2.535	$5K

Holdings After Transaction: Common Stock — 2,188 shares (Direct)

Footnotes (1)

Key Figures

Shares purchased: 2,072 shares Purchase price: $2.535 per share Shares owned after transaction: 2,188 shares +1 more

4 metrics

Shares purchased 2,072 shares Open-market purchase on March 31, 2026

Purchase price $2.535 per share Common Stock open-market transaction

Shares owned after transaction 2,188 shares Direct ownership following Form 4 trade

Net buy shares 2,072 shares Net-buy direction in transaction summary

Key Terms

open-market purchase, Common Stock, Form 4, direct ownership

4 terms

open-market purchase financial

"transaction_action: "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

direct ownership financial

"ownership_type: "direct" and ownership_code: "D""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pannu Geraldine

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		P		2,072	A	$2.535	2,188	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Geraldine Pannu by John J. Wolfel, as Attorney-in-Fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PCSA director Geraldine Pannu report?

Director Geraldine Pannu reported an open-market purchase of Processa Pharmaceuticals Common Stock. She bought 2,072 shares on March 31, 2026, increasing her direct ownership to 2,188 shares after the transaction, according to the Form 4 filing data.

At what price did Geraldine Pannu buy PCSA shares?

Geraldine Pannu purchased PCSA Common Stock at $2.535 per share. This price reflects the cost for each of the 2,072 shares acquired in the open-market transaction reported for March 31, 2026 in the Form 4 filing.

How many Processa (PCSA) shares does Geraldine Pannu own after this trade?

After the reported purchase, Geraldine Pannu directly owns 2,188 shares of Processa Pharmaceuticals Common Stock. Her holdings rose from a smaller prior position through the acquisition of 2,072 shares in an open-market transaction on March 31, 2026.

Was the PCSA insider transaction a buy or a sell?

The PCSA insider transaction was a buy. Director Geraldine Pannu executed an open-market purchase of 2,072 Common Stock shares at $2.535 per share, with no sales or derivative exercises reported in this Form 4 filing.

Does the PCSA Form 4 include any derivative securities for Geraldine Pannu?

The Form 4 for Geraldine Pannu shows no derivative securities. It reports only a non-derivative open-market purchase of 2,072 Common Stock shares and lists no options, warrants, or other derivatives in the derivative holdings summary section.